查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1866355

全球心血管支架市場－2025-2030年預測

Global Cardiovascular Stent Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計心血管支架市場將從 2025 年的 129.13 億美元成長到 2030 年的 180.18 億美元，複合年成長率為 6.89%。

由於心血管疾病盛行率不斷上升以及人口老化導致冠狀動脈阻塞患者需要接受治療，全球心血管支架市場預計將持續成長。這些支架能夠恢復狹窄或阻塞動脈的血流，透過降低心臟病發作和中風的風險來改善患者的生活品質。然而，支架植入後血栓形成的風險以及搭橋手術等替代治療方法的存在，是限制市場擴張的主要阻礙因素。

市場促進因素

心血管疾病盛行率不斷上升

心血管疾病是全球首要死因，其發生率的快速成長是推動心血管支架需求成長的主要因素。世界衛生組織（世衛組織）的報告顯示，心血管疾病佔全球每年死亡人數的32%，相當於約1,790萬人死亡。美國疾病管制與預防中心（CDC）指出，心臟相關疾病每年導致65.5萬人死亡。此外，在澳大利亞，心血管疾病影響超過400萬人，每天奪走118人的生命。壓力、不良飲食和久坐的職場環境等生活方式因素會加劇這些疾病，增加動脈阻塞，從而推動對用於恢復血流的支架的需求。隨著心血管疾病發病率的持續上升，預計到2030年，這一趨勢將推動市場成長。

人口老化加劇

人口老化是推動市場發展的主要因素，因為老年人更容易患上心血管疾病，而這些疾病需要支架來有效管理血流。根據聯合國估計，到2050年，65歲及以上人口的比例預計將達到15%，高於2020年的9.5%。這種人口結構變化正在推動對支架的需求，因為與老齡化相關的動脈功能下降需要干預以維持心血管健康，這顯著促進了支架市場的擴張。

市場限制

血栓風險和替代療法

支架植入術後血栓形成的風險是其主要限制之一。血栓阻塞血流，增加心肌梗塞和中風的風險。研究表明，1-2%的支架植入患者會出現血栓，尤其是在術後最初幾個月。儘管採取了預防措施，這種風險仍會長期存在。此外，諸如搭橋手術等替代治療方法也阻礙了支架市場的成長。對於多處動脈阻塞的患者，由於搭橋手術血栓風險較低且長期療效較佳，因此通常建議使用搭橋手術而非支架植入術。美國心臟學會的研究顯示，接受支架植入術的患者10年內死亡率為29.87%，而接受搭橋手術的患者死亡率為24.7%。主要死因是血栓引起的中風或心肌梗塞。此外，接受支架手術的患者中有 16.1% 需要再次手術，而接受搭橋手術的患者中只有 8% 需要再次手術，這表明搭橋手術的療效更佳。

市場展望

受心血管疾病盛行率上升和人口老化的影響，心血管支架市場預計將在2030年前持續成長。然而，血栓風險以及搭橋手術的競爭要求支架技術不斷進步，以提高其安全性和有效性。相關人員必須專注於創新，以應對這些挑戰，並滿足市場對微創心血管治療方案日益成長的需求。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2022-2024 年）和預測資料（2025-2030 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

5. 全球心血管支架市場（按類型分類）

  • 介紹
  • 雙效支架
  • 裸金屬支架
  • 藥物釋放型支架
  • 其他

6. 全球心血管支架市場（依材料分類）

  • 介紹
  • 聚合物
  • 金屬
    • 不銹鋼
    • 鈷鉻
    • 其他

7. 全球心血管支架市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 門診手術中心
  • 其他

8. 全球心血管支架市場（依地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 台灣
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Abbott Laboratories
  • Medtronic
  • Boston Scientific Corporation
  • B. Braun
  • Terumo Corporation
  • BIOTRONIK SE & Co. KG
  • MicroPort Scientific Corporation
  • Translumina
  • Integer Holdings Corporation
  • HEXACATH

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061611197

The Cardiovascular Stent Market is projected to rise from USD 12.913 billion in 2025 to USD 18.018 billion in 2030, driven by a 6.89% compound annual growth rate (CAGR).

The global cardiovascular stent market is poised for growth, driven by the rising prevalence of cardiovascular diseases and an aging population requiring interventions for coronary artery blockages. These stents restore blood flow in narrowed or blocked arteries, reducing risks of heart attacks and strokes, thereby improving patient quality of life. However, challenges such as the risk of blood clot formation post-stent placement and the availability of alternative treatments like bypass surgery pose significant constraints to market expansion.

Market Drivers

Rising Cardiovascular Disease Prevalence

The surge in cardiovascular diseases, the leading global cause of death, significantly drives demand for cardiovascular stents. The World Health Organization reports that these diseases account for 32% of annual deaths worldwide, equating to approximately 17.9 million fatalities. In the United States, the Centers for Disease Control and Prevention note that 655,000 deaths occur annually due to heart-related issues, while in Australia, cardiovascular conditions affect over 4 million people, claiming 118 lives daily. Lifestyle factors, including stress, poor dietary habits, and sedentary work cultures, exacerbate these conditions, increasing artery blockages and the need for stents to restore blood flow. This trend is expected to fuel market growth through 2030 as the incidence of cardiovascular issues continues to rise.

Growing Geriatric Population

The expanding geriatric demographic is a key market driver, as older individuals are more prone to cardiovascular conditions requiring stents for effective blood flow management. The United Nations projects that the global population aged 65 and above will reach 15% by 2050, up from 9.5% in 2020. This demographic shift heightens the demand for stents, as age-related artery failures necessitate interventions to maintain cardiovascular health, significantly contributing to market expansion.

Market Constraints

Risk of Blood Clots and Alternative Treatments

A major limitation is the risk of blood clot formation post-stent implantation, which can disrupt blood flow and elevate the risk of heart attacks or strokes. Research indicates that 1-2% of stent recipients develop clots, particularly in the initial months post-procedure, with risks persisting long-term despite preventive measures. Additionally, alternative treatments like bypass surgery challenge market growth. For patients with multiple artery blockages, bypass surgery is often recommended over stents due to lower clot risks and better long-term outcomes. A study by the American College of Cardiology found that 29.87% of stent patients died within 10 years compared to 24.7% of bypass surgery patients, with stroke or heart attack due to clots as the primary cause. Furthermore, 16.1% of stent patients required a second procedure, compared to 8% for bypass patients, highlighting bypass surgery's superior efficacy.

Market Outlook

The cardiovascular stent market is set to grow through 2030, driven by increasing cardiovascular disease prevalence and an aging population. However, the risk of clots and competition from bypass surgery necessitate advancements in stent technology to enhance safety and efficacy. Stakeholders must focus on innovation to address these challenges and capitalize on the growing demand for minimally invasive cardiovascular solutions.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Type

  • Dual Therapy Stent
  • Bare Metal Stent
  • Drug Eluting Stent
  • Others

By Material

  • Polymers
  • Metal
  • Stainless Steel
  • Cobalt Chromium
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CARDIOVASCULAR STENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Dual Therapy Stent
  • 5.3. Bare Metal Stent
  • 5.4. Drug Eluting Stent
  • 5.5. Others

6. GLOBAL CARDIOVASCULAR STENT MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Polymers
  • 6.3. Metal
    • 6.3.1. Stainless Steel
    • 6.3.2. Cobalt Chromium
    • 6.3.3. Others

7. GLOBAL CARDIOVASCULAR STENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. GLOBAL CARDIOVASCULAR STENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Taiwan
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott Laboratories
  • 10.2. Medtronic
  • 10.3. Boston Scientific Corporation
  • 10.4. B. Braun
  • 10.5. Terumo Corporation
  • 10.6. BIOTRONIK SE & Co. KG
  • 10.7. MicroPort Scientific Corporation
  • 10.8. Translumina
  • 10.9. Integer Holdings Corporation
  • 10.10. HEXACATH

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations